Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma

Asian Pac J Cancer Prev. 2022 Sep 1;23(9):3051-3059. doi: 10.31557/APJCP.2022.23.9.3051.

Abstract

Objective: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of astrocytoma.

Material and methods: This study used a cross-sectional design. Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133.

Results: It was found that there was a significant relationship between the expression of IDH1-R132H and CD133 in DA, AA and GB (p<0.001). Astrocytoma with IDH-mutant molecular status will express more markers of cancer stem cell CD133 than IDH-wildtype.

Conclusion: The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy.

Keywords: CD133; IDH-mutant; IDH-wildtype; IDH1-R132H; astrocytoma.

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Astrocytoma* / genetics
  • Astrocytoma* / metabolism
  • Biomarkers
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Cross-Sectional Studies
  • Glioblastoma* / genetics
  • Isocitrate Dehydrogenase / genetics
  • Isocitrate Dehydrogenase / metabolism
  • Mutation
  • Neoplastic Stem Cells / metabolism
  • Rabbits

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Isocitrate Dehydrogenase